| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 10/06/2024 | 14:30 | PR Newswire (US) | Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 31/05/2024 | 00:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 29/05/2024 | 14:45 | PR Newswire (US) | Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 29/05/2024 | 14:30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 21/05/2024 | 14:45 | PR Newswire (US) | MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 20/05/2024 | 14:00 | PR Newswire (US) | Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 13/05/2024 | 22:31 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 02/04/2024 | 14:00 | PR Newswire (US) | Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 21/03/2024 | 16:04 | PR Newswire (US) | MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 05/02/2024 | 14:30 | PR Newswire (US) | MIRA Pharmaceuticals Provides Corporate Update | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 28/12/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 27/12/2023 | 23:27 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 18/12/2023 | 22:50 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under the Securities Act of 1933 | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 04/12/2023 | 14:00 | PR Newswire (US) | MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 29/11/2023 | 14:00 | PR Newswire (US) | MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 21/11/2023 | 16:42 | PR Newswire (US) | MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 21/11/2023 | 16:09 | PR Newswire (US) | MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 20/11/2023 | 22:15 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 20/11/2023 | 14:00 | PR Newswire (US) | MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 18/09/2023 | 14:30 | PR Newswire (US) | MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 05/09/2023 | 14:31 | PR Newswire (US) | MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 31/08/2023 | 14:31 | PR Newswire (US) | MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 29/08/2023 | 17:39 | PR Newswire (US) | MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time | NASDAQ:MIRA | MIRA Pharmaceuticals Inc |
| 26/02/2009 | 23:42 | PR Newswire (US) | MAC1 Industries Corp. Merges With Tycoon Industries, LLC | NASDAQ:MIRA | |
| 15/10/2008 | 14:01 | PR Newswire (US) | Mac1 Industries Corp. Acquires Miracle Applications Corp. | NASDAQ:MIRA | |
| 03/09/2008 | 15:25 | PR Newswire (US) | Miracle Applications Corp.(MIRA) Executive Officers and Board of Directors Resign | NASDAQ:MIRA | |